Table 4.

Factors significantly associated with TTR, DOR, TTP, and OS in univariate analysis

TTR, N = 202*
DOR, n = 53*
TTP, N = 202*
OS, N = 202†
Factor
HR
P
HR
P
HR
P
HR
P
No. prior regimens, ≤5/≥6   1.337   .298   1.68   .317   1.03   .895   1.67  .027 
Type prior treatment         
    Thalidomide, Y/N   1.177   .672   NM  .033  1.79   .101   2.33  .033 
    SCT, Y/N   1.276   .408   1.93   .309   1.14   .583   1.66  .044 
Age‡, < 65, ≥65   .970  .042  2.04   .199   1.40   .138   0.98   .932  
KPS, ≤70/80/≥90   0.844   .355   0.25  .004  0.74   .055   0.62  .001 
Albumin, g/L   0.827   .436   0.11  .001  0.64   .052   0.3  <.001 
β2-microglobulin, mg/L   0.934   .137   1.04   .652   1.02  .020  1.03  .002 
C-reactive protein, g/L   0.981   .139   1.04   .085   1.02  .037  1.02  .001 
Hemoglobin, <105 g/L/≥ 105 g/L   1.398   .225   0.39   .072   0.51  .005  0.40  .001 
Bone marrow plasma cells, ≤50%/>50%   0.565   .056   2.51   .097   1.89  .009  3.66  <.001 
Platelet count, × 109/L   1.001   .593   0.99   .087   0.997  .025  0.99  <.001 
Abnormal cytogenetics, Y/N   0.506  .047  3.38  .035  2.77  <.001  2.58  <.001 
Chromosome 13 deletion, Y/N   0.867   .741   2.33   .195   1.99  .013  1.79  .04 
Stage 1, 2, or 3
 		 0.852
 		 .41
 		 1.35
 		 .37
 		 1.43
 		.024
 		 1.8
 		<.001
 
TTR, N = 202*
DOR, n = 53*
TTP, N = 202*
OS, N = 202†
Factor
HR
P
HR
P
HR
P
HR
P
No. prior regimens, ≤5/≥6   1.337   .298   1.68   .317   1.03   .895   1.67  .027 
Type prior treatment         
    Thalidomide, Y/N   1.177   .672   NM  .033  1.79   .101   2.33  .033 
    SCT, Y/N   1.276   .408   1.93   .309   1.14   .583   1.66  .044 
Age‡, < 65, ≥65   .970  .042  2.04   .199   1.40   .138   0.98   .932  
KPS, ≤70/80/≥90   0.844   .355   0.25  .004  0.74   .055   0.62  .001 
Albumin, g/L   0.827   .436   0.11  .001  0.64   .052   0.3  <.001 
β2-microglobulin, mg/L   0.934   .137   1.04   .652   1.02  .020  1.03  .002 
C-reactive protein, g/L   0.981   .139   1.04   .085   1.02  .037  1.02  .001 
Hemoglobin, <105 g/L/≥ 105 g/L   1.398   .225   0.39   .072   0.51  .005  0.40  .001 
Bone marrow plasma cells, ≤50%/>50%   0.565   .056   2.51   .097   1.89  .009  3.66  <.001 
Platelet count, × 109/L   1.001   .593   0.99   .087   0.997  .025  0.99  <.001 
Abnormal cytogenetics, Y/N   0.506  .047  3.38  .035  2.77  <.001  2.58  <.001 
Chromosome 13 deletion, Y/N   0.867   .741   2.33   .195   1.99  .013  1.79  .04 
Stage 1, 2, or 3
 		 0.852
 		 .41
 		 1.35
 		 .37
 		 1.43
 		.024
 		 1.8
 		<.001
 

Underlining represents statistical significance.

HR indicates hazard ratio; NM, not meaningful (responders without thalidomide did not progress); SCT, stem-cell transplantation; Y/N, yes/no.

*

Bortezomib alone.

†

Bortezomib ± dexamethasone.

‡

Age as a continuous factor for TTR.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal